Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.15 USD
Change Today +0.02 / 0.48%
Volume 22.8K
CBLI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 4:30 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

cleveland biolabs inc (CBLI) Snapshot

Open
$4.11
Previous Close
$4.13
Day High
$4.18
Day Low
$4.02
52 Week High
09/4/14 - $12.80
52 Week Low
05/20/15 - $1.84
Market Cap
44.5M
Average Volume 10 Days
88.0K
EPS TTM
$-2.97
Shares Outstanding
10.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLEVELAND BIOLABS INC (CBLI)

Related News

No related news articles were found.

cleveland biolabs inc (CBLI) Related Businessweek News

View More BusinessWeek News

cleveland biolabs inc (CBLI) Details

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate is Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is developing as a radiation countermeasure for prevention of death from acute radiation syndrome, and as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin. It has license agreements and collaborations with the Cleveland Clinic Foundation and Roswell Park Cancer Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

13 Employees
Last Reported Date: 05/11/15
Founded in 2003

cleveland biolabs inc (CBLI) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $302.3K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $119.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $283.2K
Compensation as of Fiscal Year 2014.

cleveland biolabs inc (CBLI) Key Developments

Cleveland BioLabs, Inc. Secures Contract Valued at Up to $9.2 Million to Support Further Development of Entolimod

Cleveland BioLabs, Inc. announced that the Department of Defense office of Congressionally Directed Medical Research Programs Joint Warfighter Medical Research Program has awarded CBLI a contract valued at up to $9.2 million to support further development of entolimod as a medical radiation countermeasure. Entolimod is a novel, broad-spectrum investigational drug being developed to mitigate the life-threatening consequences of a radiological attack. The Company has submitted an application for pre-Emergency Use Authorization (pre-EUA) to the Food and Drug Administration (FDA) in support of use of entolimod as a medical radiation countermeasure. Pre-EUA is the regulatory path through which the FDA determines that certain unapproved medical products may be used in an emergency when there are no adequate, approved, and available alternatives. Products with pre-EUA status can be purchased by certain US government stakeholders for stockpiling in the event of a disaster. The DoD contract will fund pivotal animal studies designed to support future submission of a Biologics License Application (BLA) for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster. BLA approval, if received, would be the final step necessary to reach full marketing authorization.

Cleveland BioLabs, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Cleveland BioLabs, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues from grants and contracts of $329,908 compared to $562,087 a year ago. Loss from operations was $2,850,817 against $4,012,504 a year ago. Net loss attributable to Cleveland BioLabs, Inc. was $4,444,653 or $1.12 basic and diluted per share against $3,961,161 or $1.53 basic and diluted per share a year ago. The increase in net loss was primarily attributable to non-cash charges related to the valuation of derivative warrant liabilities. The decreases in revenues related to the deconsolidation of Incuron LLC in the fourth quarter of 2014 and other variances in levels of development work reimbursable under its development contracts. For the six months, the company reported revenues from grants and contracts of $937,237 compared to $1,896,341 for the same period last year. Loss from operations was $6,162,329 against $7,531,566 a year ago. Net loss attributable to Cleveland BioLabs, Inc. was $8,094,975 or $2.25 basic and diluted per share against $5,546,533 or $2.18 basic and diluted per share a year ago. The increase in net loss was primarily attributable to non-cash charges related to the valuation of derivative warrant liabilities. The decreases in revenues related to the deconsolidation of Incuron LLC in the fourth quarter of 2014 and other variances in levels of development work reimbursable under its development contracts. Cash flows used in operating activities was $4,972,851 against $7,726,002 a year ago.

Cleveland BioLabs, Inc. to Report Q2, 2015 Results on Aug 12, 2015

Cleveland BioLabs, Inc. announced that they will report Q2, 2015 results at 10:00 AM, US Eastern Standard Time on Aug 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBLI:US $4.15 USD +0.02

CBLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBLI.
View Industry Companies
 

Industry Analysis

CBLI

Industry Average

Valuation CBLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLEVELAND BIOLABS INC, please visit www.cbiolabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.